Physician

Stanley Nabrinsky, MD

According to 2025 Medicare claims, Stanley Nabrinsky, MD (NPI: 1568459774) practices hematology/oncology in the Elgin, IL market, with the plurality of this provider's patient population coming from Kane, IL. This provider's primary affiliated billing organization is ILLINOIS CANCER SPECIALISTS (NPI: 1164483913; TIN: 363980044) and primary practice location at 60123-9405.

Nabrinsky's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 728 traditional Medicare patients, billed 209,999 HCPCS/CPT codes, and received $4,170,253 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,044 prescription claims across 220 beneficiaries totaling $4,864,606 in drug costs, led by Brukinsa (Zanubrutinib). 2022 DME data shows 12 claims. Open Payments data shows 169 records totaling $26,321. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,020,813 to $4,170,253. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,155,621 to $4,864,606. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,646 and ending at $816.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	910	137,874	$2,020,813
2016	898	181,697	$2,937,233
2017	784	124,314	$2,519,234
2018	935	158,192	$2,699,799
2019	1,004	189,549	$3,860,880
2020	934	211,354	$4,816,081
2021	907	218,807	$5,171,442
2022	847	201,542	$4,548,183
2023	830	245,891	$4,010,797
2024	728	209,999	$4,170,253

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	212	1,241	$1,155,621
2016	214	1,304	$1,859,574
2017	207	1,313	$2,743,439
2018	218	1,241	$2,586,669
2019	240	1,281	$2,495,259
2020	223	1,442	$3,334,390
2021	257	1,410	$3,858,320
2022	216	1,094	$3,595,854
2023	203	965	$3,575,367
2024	220	1,044	$4,864,606

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	123	$55,600
2016	28	152	$57,875
2017	26	111	$19,309
2018	11	98	$14,468
2019	N/R	44	$6,403
2020	N/R	25	$2,265
2021	12	58	$3,400
2022	N/R	12	$901
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	176	372	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	330	1,637	$71
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	219	465	$63
36415	Insertion of needle into vein for collection of blood sample	412	1,886	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	418	1,908	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	44	1,320	$661,901
Lenalidomide	Lenalidomide	32	896	$442,086
Ayvakit	Avapritinib	11	330	$418,020
Kisqali	Ribociclib Succinate	24	672	$405,983
Jakafi	Ruxolitinib Phosphate	18	540	$307,406

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	169	$26,321	EMD Serono, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Stanley Nabrinsky, MD?

Tedicare shows public-source Medicare data for Stanley Nabrinsky, MD (NPI 1568459774), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Stanley Nabrinsky, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Stanley Nabrinsky, MD?

Stanley Nabrinsky, MD is linked to ILLINOIS CANCER SPECIALISTS (billing NPI 1164483913) in the available physician profile data.

Does Stanley Nabrinsky, MD have Open Payments data?

Stanley Nabrinsky, MD has 169 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.